Why Experts Are Sounding the Alarm Over the New Cicada COVID Variant Emerging After Two Years Underground

Just as many believed the most unpredictable phase of the COVID-19 pandemic had passed, a newly identified variant has begun to draw attention for its unusual behavior and rapid spread. Informally nicknamed “Cicada,” this strain—scientifically labeled BA.3.2—has sparked concern among virologists and public health experts as it appears across multiple regions worldwide, including dozens of reported cases throughout the United States.

The name “Cicada” reflects a striking characteristic of the variant’s timeline. Much like the insect known for remaining dormant underground for years before emerging in large numbers, BA.3.2 was first detected as early as late 2024, quietly circulating at minimal levels. For a long period, it remained largely unnoticed in global tracking systems. Then, in early 2026, infection rates tied to this strain began to climb more noticeably, particularly in parts of Europe and North America, suggesting a delayed but significant resurgence.

What sets this variant apart is its genetic complexity. Researchers have identified an unusually high number of mutations—estimated between 70 and 75—concentrated in the spike protein, the part of the virus responsible for attaching to human cells. This makes BA.3.2 one of the most heavily mutated strains observed since the emergence of earlier Omicron variants. Because of these changes, the immune system may not recognize it as effectively as it does more familiar strains.

Early laboratory findings indicate that this variant has a heightened ability to partially evade immune defenses. Antibodies produced from prior infections or recent vaccinations appear less efficient at neutralizing it. In certain countries, including Denmark and Germany, the strain has already become a noticeable portion of sequenced cases, suggesting it may spread more easily in populations with existing immunity.

Despite these concerns, there are also reassuring signs. Current data does not show that BA.3.2 leads to more severe illness compared to other recent variants. Reported symptoms remain broadly consistent with Omicron-related infections, including sore throat, fatigue, congestion, and coughing. Some individuals have also reported increased night sweating, though more severe symptoms like loss of taste or smell remain uncommon.

Importantly, while protection against infection may be reduced, vaccines still appear to offer strong defense against serious outcomes such as hospitalization and death. This is largely due to the body’s T-cell response, which continues to recognize and respond to the virus even when antibody effectiveness declines.

As of now, the variant represents a relatively small percentage of total infections in many areas. However, wastewater monitoring has detected its presence across a wide geographic range, indicating that it may be spreading more broadly than confirmed case numbers suggest. This highlights the importance of continued monitoring and preparedness.

The emergence of BA.3.2 serves as a reminder that the virus continues to evolve in unexpected ways. While it does not currently appear to pose a dramatically increased threat, its ability to adapt underscores the need for ongoing vigilance, updated research, and a flexible public health response.